A Simple New Blood Test May Help Doctors See How Far Alzheimer's Has Advanced in the Brain

On the left, a healthcare worker in gloves holds a blood sample vial; on the right, a doctor comforts an elderly patient.

Advances in blood-based biomarkers have been reshaping how clinicians think about diagnosing and monitoring Alzheimer’s disease. A new study adds an important piece to that puzzle by introducing a blood test that could make measuring advanced Alzheimer’s disease more accessible, especially in places without cutting-edge imaging or specialized laboratories. This new approach focuses on eMTBR-tau, a tau protein fragment that appears to reflect the spread of neurofibrillary tangles, a core feature of advanced Alzheimer’s pathology.

Alzheimer’s disease is known for two hallmark brain changes: amyloid-beta plaques and neurofibrillary tangles made up of aggregated tau protein. In recent years, blood tests detecting phosphorylated tau 217, or p-tau217, have emerged as powerful tools for identifying Alzheimer’s-related amyloid pathology in its earlier, more subtle stages. Those tests have helped distinguish Alzheimer’s from other forms of cognitive decline much more easily than before. Yet they provide limited insight into how far tau tangles have actually spread through the brain, which is more closely tied to the severity of symptoms and the stage of disease.

A healthcare provider in a white coat gently holds the hands of an elderly patient seated on a medical exam table.

The new work addresses that gap by homing in on eMTBR-tau, specifically a form known as eMTBR-tau243. Earlier research in 2025 and 2026 linked higher levels of this biomarker in blood to greater tau accumulation in the brain and faster cognitive decline. The challenge was that measuring eMTBR-tau relied on mass spectrometry, a sophisticated laboratory method that requires large sample volumes and specialized equipment available in relatively few centers. That reality limited the biomarker’s use in routine clinical care or large-scale screening, even as evidence for its value continued to grow.

Researchers from Banner Sun Health Research Institute in Arizona, Lund University in Sweden, and several collaborating institutions have now developed a new immunoassay that can quantify eMTBR-tau more simply and efficiently. Rather than relying on mass spectrometry, this test uses a laboratory platform that many diagnostic centers already know well. In a JAMA publication describing their work, the team reports that the immunoassay’s performance in identifying advanced tau pathology was comparable to the more complex mass spectrometry approach.

A healthcare worker wearing blue gloves holds a blood sample vial while attending to a patient in a medical laboratory.

To understand how well the assay reflects actual disease in the brain, investigators examined blood samples from 728 individuals in total. This included 521 brain donors from two United States autopsy cohorts and 207 participants from imaging studies conducted in Canada and Sweden. That design allowed the team to compare blood measurements with both postmortem pathological findings and tau-PET imaging, two of the most trusted methods for tracking tau pathology.

Among the brain donors, the differences in eMTBR-tau levels between early and advanced disease were striking. Concentrations were 25.2 to 50.5 times higher in individuals with the most advanced tau pathology, classified as Braak stage VI, than in those at Braak stages I or II. Braak staging is a commonly used system that describes how far tau tangles have spread throughout the brain, from initial involvement of deeper structures to widespread distribution in the cerebral cortex. By the time patients reach Braak stage VI, tau tangles are extensive and typically associated with severe cognitive impairment.

In an imaging cohort that underwent tau-PET scanning, the pattern was similar. Participants with advanced tau pathology had eMTBR-tau concentrations that were nearly 60 times higher than those with no detectable tau abnormalities on PET. The researchers noted that many of the values in the comparison groups fell below the assay’s quantification limit, a reminder that measuring very low levels can be technically challenging. Even so, when they applied more conservative statistical approaches, the differences between individuals with and without advanced tau pathology remained substantial.

The new Alzheimer’s blood test did not just show large group differences. It also demonstrated strong diagnostic accuracy when used to distinguish individuals with tau pathology on PET from those without. In these analyses, the assay achieved areas under the curve between 0.96 and 0.99, which are generally considered excellent and were comparable to what had previously been achieved with mass spectrometry measurements of eMTBR-tau. In a further autopsy-based analysis, eMTBR-tau showed a tighter association with overall tau tangle burden than either standard p-tau217 or a brain-derived version of p-tau217, underscoring its potential as a marker of disease stage rather than just disease presence.

Practical considerations are also central to whether a new biomarker can transform care. Here, the immunoassay offers clear advantages. It requires only 35 microliters of plasma compared with 1.5 milliliters needed for mass spectrometry. It also avoids the intricate sample preparation and specialized instrumentation that have limited mass spectrometry to a relatively small number of reference laboratories. By relying on a more scalable laboratory method, this advanced Alzheimer’s blood test could eventually become available in a wider range of clinical and research settings.

The study’s authors emphasize that p-tau217 and eMTBR-tau are not competing tools, but complementary ones. p-tau217 appears particularly effective at flagging the early presence of Alzheimer’s-related changes, especially amyloid pathology. eMTBR-tau, by contrast, seems to capture how far tau tangles have spread, which may be more closely related to current symptoms and overall disease severity. One of the co-senior authors, Niklas Mattsson-Carlgren, MD, PhD, highlighted that a major challenge in Alzheimer’s diagnosis is not only establishing that Alzheimer’s pathology is present but confirming that it has reached a sufficiently advanced stage to plausibly explain a person’s cognitive symptoms. The combination of these two biomarkers could help meet that need more confidently.

Senior author Nicholas Ashton, PhD, who leads the Fluid Biomarker Program at Banner Sun Health Research Institute, noted that while p-tau217 detects early signs of disease, eMTBR-tau offers a window into the extent of tau tangle spread. In practical terms, this pairing could help clinicians make more informed treatment decisions, such as identifying which patients might benefit from certain disease-modifying therapies and which individuals are more suitable for specific clinical trials. For researchers, a scalable, reliable measure of advanced tau pathology could improve how Alzheimer’s disease is staged, making it easier to select participants, monitor progression, and assess responses to interventions.

I found this detail particularly compelling: by narrowing the technical gap between cutting-edge biomarker research and everyday clinical practice, tests like this one could eventually reduce reliance on expensive, less accessible tools such as tau-PET imaging. While more validation and real-world implementation studies will be needed, the development of a practical eMTBR-tau immunoassay represents a meaningful step toward more accessible, biologically informed care for people living with or at risk of advanced Alzheimer’s disease.

Read more at https://www.insideprecisionmedicine.com/topics/molecular-dx/new-blood-test-could-make-measuring-advanced-alzheimers-disease-more-accessible/

Back to blog
Customers Also Viewed

Beat the Rush, Shop Now for
the Best Selection

Recommended Just For You
Recently Viewed & Trending Items
DEV MODE ACTIVE. BRAND: gg